Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272478 | 0.88 | FAAH (0.50) | DGAT1ALDH1A1SMN1; SMN2GLAFAAH | |
| SCHEMBL3269574 | 0.84 | DGAT1 (0.44) | DGAT1ALDH1A1SMN1; SMN2FAAHCA12 | |
| SCHEMBL3270509 | 0.82 | FAAH (0.49) | DGAT1ALDH1A1SMN1; SMN2GLAFAAH | |
| SCHEMBL3267735 | 0.80 | CSNK1D (0.47) | DGAT1SMN1; SMN2FAAHCA12CA1 | |
| SCHEMBL3269282 | 0.80 | POLB (0.60) | SMN1; SMN2GLAFAAHCA12CA1 | |
| SCHEMBL3269311 | 0.77 | FAAH (0.65) | FAAHHTTMAPTUSP2MEN1 | |
| SCHEMBL3275452 | 0.77 | TRPV1 (0.52) | GLAFAAHHTTMAPTUSP2 | |
| SCHEMBL3274584 | 0.76 | FAAH (0.51) | ALDH1A1SMN1; SMN2FAAHHTTMAPT | |
| SCHEMBL3269233 | 0.72 | FAAH (0.49) | DGAT1ALDH1A1SMN1; SMN2FAAHCA12 | |
| SCHEMBL3274026 | 0.72 | FAAH (0.64) | ALDH1A1SMN1; SMN2GLAFAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2199282-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | DGAT1 256/4885ALDH1A1 259/4885SMN1; SMN2 3410/4885 |
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | DGAT1 256/4885ALDH1A1 259/4885SMN1; SMN2 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.